These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 25360618)
1. Design novel inhibitors for treating cancer by targeting Cdc25B catalytic domain with de novo design. Wu JW; Zhang H; Duan YQ; Dong WL; Cheng XC; Wang SQ; Wang RL Comb Chem High Throughput Screen; 2014; 17(10):837-47. PubMed ID: 25360618 [TBL] [Abstract][Full Text] [Related]
2. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches. Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259 [TBL] [Abstract][Full Text] [Related]
3. Discovery of new inhibitors of Cdc25B dual specificity phosphatases by structure-based virtual screening. Lavecchia A; Di Giovanni C; Pesapane A; Montuori N; Ragno P; Martucci NM; Masullo M; De Vendittis E; Novellino E J Med Chem; 2012 May; 55(9):4142-58. PubMed ID: 22524450 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. George Rosenker KM; Paquette WD; Johnston PA; Sharlow ER; Vogt A; Bakan A; Lazo JS; Wipf P Bioorg Med Chem; 2015 Jun; 23(12):2810-8. PubMed ID: 25703307 [TBL] [Abstract][Full Text] [Related]
5. Insights into the interaction of high potency inhibitor IRC-083864 with phosphatase CDC25. Sarkis M; Miteva MA; Dasso Lang MC; Jaouen M; Sari MA; Galcéra MO; Ethève-Quelquejeu M; Garbay C; Bertho G; Braud E Proteins; 2017 Apr; 85(4):593-601. PubMed ID: 28056492 [TBL] [Abstract][Full Text] [Related]
7. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B. Ma Y; Li HL; Chen XB; Jin WY; Zhou H; Ma Y; Wang RL Comput Biol Chem; 2018 Apr; 73():1-12. PubMed ID: 29413811 [TBL] [Abstract][Full Text] [Related]
8. Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Park H; Bahn YJ; Ryu SE Bioorg Med Chem Lett; 2009 Aug; 19(15):4330-4. PubMed ID: 19497739 [TBL] [Abstract][Full Text] [Related]
9. Structure-based virtual screening approach to identify novel classes of Cdc25B phosphatase inhibitors. Park H; Li M; Choi J; Cho H; Ham SW Bioorg Med Chem Lett; 2009 Aug; 19(15):4372-5. PubMed ID: 19500977 [TBL] [Abstract][Full Text] [Related]
10. CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy. Lavecchia A; Di Giovanni C; Novellino E Curr Med Chem; 2009; 16(15):1831-49. PubMed ID: 19442149 [TBL] [Abstract][Full Text] [Related]
11. Identification of the quinolinedione inhibitor binding site in Cdc25 phosphatase B through docking and molecular dynamics simulations. Ge Y; van der Kamp M; Malaisree M; Liu D; Liu Y; Mulholland AJ J Comput Aided Mol Des; 2017 Nov; 31(11):995-1007. PubMed ID: 28994029 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and functional evaluation of triazine-based bivalent agents that simultaneously target the active site and hot spot of phosphatase Cdc25B. Nagaoka Y; Parvatkar P; Hirai G; Ohkanda J Bioorg Med Chem Lett; 2021 Sep; 48():128265. PubMed ID: 34273487 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity. Brun MP; Braud E; Angotti D; Mondésert O; Quaranta M; Montes M; Miteva M; Gresh N; Ducommun B; Garbay C Bioorg Med Chem; 2005 Aug; 13(16):4871-9. PubMed ID: 15921913 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel coumarin-based inhibitors of Cdc25 phosphatases. Valente S; Bana E; Viry E; Bagrel D; Kirsch G Bioorg Med Chem Lett; 2010 Oct; 20(19):5827-30. PubMed ID: 20800482 [TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review. Lavecchia A; Di Giovanni C; Novellino E Expert Opin Ther Pat; 2010 Mar; 20(3):405-25. PubMed ID: 20166845 [TBL] [Abstract][Full Text] [Related]
16. Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library. Johnston PA; Foster CA; Tierno MB; Shun TY; Shinde SN; Paquette WD; Brummond KM; Wipf P; Lazo JS Assay Drug Dev Technol; 2009 Jun; 7(3):250-65. PubMed ID: 19530895 [TBL] [Abstract][Full Text] [Related]
17. Structure-based development of novel triazoles and related thiazolotriazoles as anticancer agents and Cdc25A/B phosphatase inhibitors. Synthesis, in vitro biological evaluation, molecular docking and in silico ADME-T studies. Rostom SAF; Badr MH; Abd El Razik HA; Ashour HMA Eur J Med Chem; 2017 Oct; 139():263-279. PubMed ID: 28803043 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of CDC25B phosphatase through disruption of protein-protein interaction. Lund G; Dudkin S; Borkin D; Ni W; Grembecka J; Cierpicki T ACS Chem Biol; 2015 Feb; 10(2):390-4. PubMed ID: 25423142 [TBL] [Abstract][Full Text] [Related]
19. Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. Jing L; Wu G; Hao X; Olotu FA; Kang D; Chen CH; Lee KH; Soliman MES; Liu X; Song Y; Zhan P Eur J Med Chem; 2019 Dec; 183():111696. PubMed ID: 31541869 [TBL] [Abstract][Full Text] [Related]